Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
McKesson
Mallinckrodt
McKinsey
Boehringer Ingelheim

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR IDARUBICIN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Idarubicin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002517 ↗ Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1993-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute myeloid leukemia or myelodysplastic syndrome. PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating children who have newly diagnosed acute myeloid leukemia or myelodysplastic syndrome.
NCT00002532 ↗ Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia Unknown status Hannover Medical School Phase 2 1993-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed or refractory acute lymphocytic leukemia.
NCT00002549 ↗ Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1993-11-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy followed by bone marrow or peripheral stem cell transplantation in treating patients with acute myelogenous leukemia.
NCT00002565 ↗ Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma Completed National Cancer Institute (NCI) Phase 3 1994-05-25 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for intermediate-grade or immunoblastic non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have intermediate-grade or immunoblastic non-Hodgkin's lymphoma.
NCT00002565 ↗ Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma Completed M.D. Anderson Cancer Center Phase 3 1994-05-25 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for intermediate-grade or immunoblastic non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have intermediate-grade or immunoblastic non-Hodgkin's lymphoma.
NCT00002609 ↗ Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission Completed National Cancer Institute (NCI) Phase 2 1994-08-01 RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them, without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus monoclonal antibody therapy in treating patients with acute promyelocytic leukemia in remission.
NCT00002609 ↗ Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission Completed Memorial Sloan Kettering Cancer Center Phase 2 1994-08-01 RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them, without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus monoclonal antibody therapy in treating patients with acute promyelocytic leukemia in remission.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Idarubicin Hydrochloride

Condition Name

Condition Name for Idarubicin Hydrochloride
Intervention Trials
Acute Myeloid Leukemia 76
Leukemia 60
Untreated Adult Acute Myeloid Leukemia 15
Myelodysplastic Syndromes 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Idarubicin Hydrochloride
Intervention Trials
Leukemia 209
Leukemia, Myeloid 171
Leukemia, Myeloid, Acute 169
Myelodysplastic Syndromes 45
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Idarubicin Hydrochloride

Trials by Country

Trials by Country for Idarubicin Hydrochloride
Location Trials
United States 698
Spain 69
Japan 62
Germany 60
Canada 60
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Idarubicin Hydrochloride
Location Trials
Texas 59
California 44
New York 39
Illinois 31
Ohio 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Idarubicin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Idarubicin Hydrochloride
Clinical Trial Phase Trials
Phase 4 18
Phase 3 63
Phase 2/Phase 3 12
[disabled in preview] 164
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Idarubicin Hydrochloride
Clinical Trial Phase Trials
Completed 127
Recruiting 45
Unknown status 43
[disabled in preview] 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Idarubicin Hydrochloride

Sponsor Name

Sponsor Name for Idarubicin Hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 51
M.D. Anderson Cancer Center 23
PETHEMA Foundation 15
[disabled in preview] 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Idarubicin Hydrochloride
Sponsor Trials
Other 292
Industry 82
NIH 53
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Harvard Business School
Dow
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.